X T L Biopharmaceuticals Ltd
TASE:XTLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
X T L Biopharmaceuticals Ltd
Cash from Operating Activities
X T L Biopharmaceuticals Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
X
|
X T L Biopharmaceuticals Ltd
TASE:XTLB
|
Cash from Operating Activities
-$820k
|
CAGR 3-Years
23%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash from Operating Activities
$25.5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash from Operating Activities
-$10.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash from Operating Activities
-$162.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash from Operating Activities
-$7.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cash from Operating Activities
-$20.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-1%
|
|
X T L Biopharmaceuticals Ltd
Glance View
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). hCDR1 is a peptide (short protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
See Also
What is X T L Biopharmaceuticals Ltd's Cash from Operating Activities?
Cash from Operating Activities
-820k
USD
Based on the financial report for Dec 31, 2018, X T L Biopharmaceuticals Ltd's Cash from Operating Activities amounts to -820k USD.
What is X T L Biopharmaceuticals Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
20%
Over the last year, the Cash from Operating Activities growth was 27%. The average annual Cash from Operating Activities growth rates for X T L Biopharmaceuticals Ltd have been 23% over the past three years , 20% over the past five years .
